Navigation Links
Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
Date:10/22/2008

file status and pending litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the use of legal, regulatory and legislative strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
2. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
3. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
4. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
7. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
8. Mylan to Host Investor Day on October 3, 2007
9. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
10. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
11. Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... December 14 , - ... of,Women With Rheumatoid Arthritis in Seven Major Industrialized Countries , ... with rheumatoid arthritis say their disease, ... - Women living with rheumatoid arthritis find shopping for ... cards and wrapping presents most, ...
(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused ... therapeutics for cardiovascular and muscle disease, today announced ... plays a crucial role in the progression of ... and in neuromuscular synaptic regeneration in mice. ... of the journal Science , reveal miR-206 ...
(Date:12/11/2009)... DIEGO, Dec. 11 Ambit Biosciences Corporation announced ... Texas M. D. Anderson Cancer Center of the first ... Monotherapy E fficacy) Phase 2 pivotal ... leukemia (AML). AC220 is a novel, orally available, ... designed as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. ...
(Date:12/11/2009)... Dec. 11 Gwathmey, Inc., a pre-clinical ... cancer, staph aureus, and cardiovascular disease announces a ... today that Rosalie Dunn, Ph.D., has joined Gwathmey ... over 28 years of experience working with small ... joining Gwathmey, Dr. Dunn managed multimillion dollar portfolios ...
Breaking Biology Technology:Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2
... the second month in a row,the capital markets succumbed to ... of the month the Dow dropped over 300 points after,oil ... Amid these,fears, biotech was dragged down with the Burrill Biotech ... the Dow, which closed down,3%., "The biotech sector started ...
... COPENHAGEN, Denmark and LELYSTAD, Netherlands, March 3, Genmab ... of a research collaboration aimed at identifying fully,human ... those that are difficult to address using,commonly available ... antibodies. These difficulties can for example be due ...
... Pathology LIS Interface to Digital Pathology Information ... ... 3 IMPAC Medical,Systems, Inc. (IMPAC), an Elekta company and ... Aperio Technologies, (Aperio) a global leader in digital pathology for,the ...
Other Biology Technology:Biotech Drops Amid Tough Markets in February 2Biotech Drops Amid Tough Markets in February 3Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 2Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 3IMPAC Medical Systems and Aperio to Develop Integrated Solution for Anatomic Pathology 2IMPAC Medical Systems and Aperio to Develop Integrated Solution for Anatomic Pathology 3
(Date:12/14/2009)... The most comprehensive study to date of the ... appendages may provide important clues to how similar regeneration ... the School of Science at Indiana University-Purdue University Indianapolis ... amputated limbs of axolotls, a type of salamander that ... any level of amputation, with the hope that this ...
(Date:12/14/2009)... A team of researchers from the Astrobiology Centre (INTA-CSIC) ... considered essential to the formation of the most basic ... blue. In order to carry out this study, published ... scientists recreated the chemical conditions of the early Earth. ... dissolved in ammoniac solutions it produces hydrogen cyanide, a ...
(Date:12/14/2009)... support of the United Nations Framework Convention on ... Environment Agency hosted the ,Bend the Trend, event ... networking platform and premiere the screening of the ... Atlas of Europe, a joint project of the ... (UNEP) and ESA, is a series of short ...
Breaking Biology News(10 mins):IUPUI researchers tackle protein mechanisms behind limb regeneration 2Prussian blue linked to the origin of life 2'Environmental Atlas of Europe' unveiled at COP15 2Mountain Home Helps Companies Battle Tough Economic Times by Offering Free Lean Six Sigma Training 58111 1Mountain Home Helps Companies Battle Tough Economic Times by Offering Free Lean Six Sigma Training 58111 2Webinar Series Launches for Eye Care Personnel 58108 1Webinar Series Launches for Eye Care Personnel 58108 2Webinar Series Launches for Eye Care Personnel 58108 3Webinar Series Launches for Eye Care Personnel 58108 4NAMSA Unveils New Larger State of the Art Analytical Chemistry Facility 58105 1NAMSA Unveils New Larger State of the Art Analytical Chemistry Facility 58105 2
... Savant's latest SpeedVac Concentrator, the SPD series ... a new modern twist., The SPD121P SpeedVac ... gauge for optimizing runs; preventing samples from ... stopped at the end-users preset level., Standard ...
... hybridization ovens are designed to create the ideal ... control (ambient to 99.9C) , Variable speed ... of samples, whether it be for washing or ... the current temperature inside the chamber, ,is situated ...
... is the latest edition to the famous ... an extra large diameter exhaust port for ... panel allows precise setting and control of ... handling large quantities and samples , ...
... Thermo Savant SpeedVac™ Concentrators set the standard for ... SC210A SpeedVac with large chamber uses a combination ... multiple samples in a single run. , SC210A ... Chamber for long lasting chemical compatibility ...
Biology Products: